{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+%28PBO%29",
    "query": {
      "intervention": "placebo (PBO)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 164,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=placebo+%28PBO%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-11-02T05:46:45.301Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06538558",
      "title": "Study to Assess the Use of Tezampanel for Opioid Withdrawal Syndrome in Treatment-Seeking Patients With Opioid Use Disorder",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "Tezampanel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Proniras Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 40,
      "start_date": "2024-10-16",
      "completion_date": "2027-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-11-02T05:46:45.301Z",
      "location_count": 1,
      "location_summary": "Indianapolis, Indiana",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06538558"
    },
    {
      "nct_id": "NCT03247530",
      "title": "Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "ADHD"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "100mg SPN-812",
          "type": "DRUG"
        },
        {
          "name": "200mg SPN-812",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Supernus Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "6 Years to 11 Years"
      },
      "enrollment_count": 477,
      "start_date": "2017-10-20",
      "completion_date": "2018-09-12",
      "has_results": true,
      "last_update_posted_date": "2021-07-02",
      "last_synced_at": "2026-11-02T05:46:45.301Z",
      "location_count": 7,
      "location_summary": "Dothan, Alabama • Hialeah, Florida • Meridian, Idaho + 4 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Meridian",
          "state": "Idaho"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03247530"
    },
    {
      "nct_id": "NCT02563769",
      "title": "Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cocaine Dependence",
        "Cocaine Addiction",
        "Cocaine Abuse",
        "Cocaine-Related Disorders"
      ],
      "interventions": [
        {
          "name": "Clavulanic acid",
          "type": "DRUG"
        },
        {
          "name": "Intravenous cocaine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Temple University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2016-10-24",
      "completion_date": "2018-05-25",
      "has_results": true,
      "last_update_posted_date": "2023-11-03",
      "last_synced_at": "2026-11-02T05:46:45.301Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02563769"
    },
    {
      "nct_id": "NCT03370133",
      "title": "A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Plaque Psoriasis",
        "Moderate to Severe Chronic Plaque Psoriasis",
        "Psoriatic Arthritis"
      ],
      "interventions": [
        {
          "name": "Bimekizumab",
          "type": "DRUG"
        },
        {
          "name": "Ustekinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma SRL",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 567,
      "start_date": "2017-12-06",
      "completion_date": "2019-12-13",
      "has_results": true,
      "last_update_posted_date": "2026-04-15",
      "last_synced_at": "2026-11-02T05:46:45.301Z",
      "location_count": 25,
      "location_summary": "Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03370133"
    },
    {
      "nct_id": "NCT00200902",
      "title": "Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Depression"
      ],
      "interventions": [
        {
          "name": "Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Interpersonal Clinical Interaction (ICI)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "University of California, Los Angeles",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 88,
      "start_date": "2005-08",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2024-08-13",
      "last_synced_at": "2026-11-02T05:46:45.301Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00200902"
    },
    {
      "nct_id": "NCT04622007",
      "title": "Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Tomivosertib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Effector Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2021-06-02",
      "completion_date": "2024-12-09",
      "has_results": false,
      "last_update_posted_date": "2024-04-30",
      "last_synced_at": "2026-11-02T05:46:45.301Z",
      "location_count": 131,
      "location_summary": "Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 105 more",
      "locations": [
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04622007"
    },
    {
      "nct_id": "NCT00743145",
      "title": "Effects of Low-dose Naltrexone in Combination With a Range of Smoked Marijuana",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Marijuana Smoking"
      ],
      "interventions": [
        {
          "name": "Inactive Marijuana (0% THC)",
          "type": "DRUG"
        },
        {
          "name": "Active Marijuana (5.5% THC)",
          "type": "DRUG"
        },
        {
          "name": "Active Marijuana (6.2% THC)",
          "type": "DRUG"
        },
        {
          "name": "Naltrexone",
          "type": "DRUG"
        },
        {
          "name": "Placebo naltrexone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "21 Years to 45 Years"
      },
      "enrollment_count": 23,
      "start_date": "2008-05",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2018-09-14",
      "last_synced_at": "2026-11-02T05:46:45.301Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00743145"
    },
    {
      "nct_id": "NCT02477839",
      "title": "Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects ≥1 Month to <4 Years With Partial-onset Seizures",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Epilepsy With Partial-onset Seizures"
      ],
      "interventions": [
        {
          "name": "Lacosamide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "UCB BIOSCIENCES, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "47 Months",
        "sex": "ALL",
        "summary": "1 Month to 47 Months"
      },
      "enrollment_count": 255,
      "start_date": "2015-06-05",
      "completion_date": "2020-05-28",
      "has_results": true,
      "last_update_posted_date": "2021-07-01",
      "last_synced_at": "2026-11-02T05:46:45.301Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Tampa, Florida • Henderson, Nevada + 3 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Henderson",
          "state": "Nevada"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02477839"
    },
    {
      "nct_id": "NCT04099667",
      "title": "Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Spasticity"
      ],
      "interventions": [
        {
          "name": "Phase 2; Low Dose MYOBLOC (15,000 Units)",
          "type": "DRUG"
        },
        {
          "name": "Phase 2; High Dose MYOBLOC (20,000 Units)",
          "type": "DRUG"
        },
        {
          "name": "Phase 2; Placebo",
          "type": "DRUG"
        },
        {
          "name": "Phase 3; MYOBLOC",
          "type": "DRUG"
        },
        {
          "name": "Phase 3; Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 40,
      "start_date": "2019-12-17",
      "completion_date": "2023-03-24",
      "has_results": true,
      "last_update_posted_date": "2026-05-22",
      "last_synced_at": "2026-11-02T05:46:45.301Z",
      "location_count": 4,
      "location_summary": "Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more",
      "locations": [
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Port Royal",
          "state": "South Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04099667"
    },
    {
      "nct_id": "NCT02326298",
      "title": "An Efficacy and Safety Study of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis",
        "Plaque Psoriasis"
      ],
      "interventions": [
        {
          "name": "Certolizumab Pegol",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "UCB Biopharma S.P.R.L.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 234,
      "start_date": "2014-12-16",
      "completion_date": "2018-10-24",
      "has_results": true,
      "last_update_posted_date": "2019-11-07",
      "last_synced_at": "2026-11-02T05:46:45.301Z",
      "location_count": 8,
      "location_summary": "San Diego, California • West Des Moines, Iowa • Baton Rouge, Louisiana + 5 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "West Des Moines",
          "state": "Iowa"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02326298"
    }
  ]
}